SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

Surgery remains soc in low risk EBC

Giredestrant will replace current adjuvant therapy

Revolution in adjuvant endocrine therapy?

AI based prognostic test

Therapy optimization: Endocrine approaches in…

SERDs in early breast cancer - the new era has begun?

ALTTO trial outcome according to endocrine therapy

SERDs now in adjuvant therapy

ctDNA analysis could optimize the approach in HER2+

Quality of live data DB11

sTILs with deep learning AI

Safety data DB11

Optimized endocrine therapy for premenopausal patients

Platinum adjuvant in TNBC

In addition to pCR, ctDNA is prognostically relevant…

Olaparib neoadjuvant with high PCR rates

Carboplatino nel contesto adiuvante del TNBC

Risultati dello studio ALTTO in base alla terapia…

La chirurgia rimane lo standard di cura nei casi di…

Otimização da terapia: abordagens endócrinas em…

El análisis del ADN libre circulante podría optimizar…

Phase 2 combination of elacestrant with everolimus or…

Biomarker and clinical subgroup analysis of evERA…

ASCENT-07 a negative trial

Updated results of VIKTORIA-1

Triple-positive MBC: less chemotherapy, more endocrine…

Chemotherapy-free treatment: a promising therapeutic…

No improvement over standard therapy

Elacestrant as oral endocrine backbone

Traditional chemotherapy should not be forgotten as…

The significance of SG is more clearly defined

Make a hot tumor out of a cold tumor

Elacestrant is a good combination partner for HR+ HER2+…

Monitoring of ILD

CDK4/6 inhibitor + endocrine therapy remains the…

Maintenance therapy HER2+ Tucatinib as a new option

ctDNA Dynamics as a biomarker of response

Tucatinib a new SERD in the adjuvant setting

Significant innovations in early and metastatic HER2+…

Nuove prove a favore dei SERD orali

Résultats actualisés de VIKTORIA-1

Jeszcze nie czas na rezygnację z tradycyjnej…

La dinamica del ctDNA come biomarcatore di risposta

Risultati aggiornati di VIKTORIA-1

Tucatinib, un nouveau SERD dans le cadre d'un…

Sem melhorias em relação à terapia padrão